Pharmacogenetics of irinotecan and oxaliplatin in advanced colorectal cancer Kweekel, D.M.

Our data suggest that there is no association between GSTP1 Ile/Val genotype and neurotoxicity in patients who received ≥500 mg/m 2 oxaliplatin, although an increased

To identify new polymorphisms (SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced

Our study also does not confirm the association between the GSTP1 genotype and OS (or PFS) in patients receiving second-line oxaliplatin plus capecitabine for advanced

This thesis focuses on the study of various genetic polymorphisms with regard to the efficacy and toxicity of oxaliplatin and irinotecan in metastatic colorectal

Hoewel in sommige studies bij gastro-intestinale tumoren is gevonden dat patiënten met het Val/Val genotype, behandeld met oxaliplatin, een langere totale overleving

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.. GSTP1 Ile105Val polymorphism

de geneeskunde niet gericht is op datgene wat de gezondheid bevordert van Sokrates of Kallias, maar op dat wat de gezondheid van zo iemand of zulke

Peripheral blood cells were stained with HLA-A2.1 tetramers containing the tyrosinase368–376 peptide followed by staining with a panel of lineage antibodies, as described in